

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

Precautionary statements :

Prevention:
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
P405 Store locked up.

Hazardous components which must be listed on the label:

Lynestrenol

Additional Labelling

EUH208 Contains Tocopherol.
May produce an allergic reaction.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Lynestrenol	52-76-6 200-151-4	Acute Tox. 4; H302 Muta. 1B; H340 Carc. 2; H351 Repr. 1A; H360Fd STOT RE 1; H372 (Blood, Mammary gland, Uterus (including cervix), Ovary)	>= 1 - < 10
Tocopherol	10191-41-0 233-466-0	Skin Sens. 1B; H317	>= 0,1 - < 1

For explanation of abbreviations see section 16.

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

SECTION 4: First aid measures**4.1 Description of first aid measures**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : May cause genetic defects.
Suspected of causing cancer.
May damage fertility. Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- May produce an allergic reaction.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.
-

SECTION 5: Firefighting measures**5.1 Extinguishing media**

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
-

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

mine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

- | | | |
|-------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases |

SAFETY DATA SHEET



Lynestrenol Formulation



Version 3.4 Revision Date: 09.04.2021 SDS Number: 449559-00011 Date of last issue: 10.10.2020
Date of first issue: 15.01.2016

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Starch	9005-25-8	TWA OEL-RL (Respirable dust)	5 mg/m ³	ZA OEL
Further information: Recommended Limit				
		TWA OEL-RL (inhalable dust)	10 mg/m ³	ZA OEL
Further information: Recommended Limit				
Lynestrenol	52-76-6	TWA	1 µg/m ³ (OEB 4)	Internal
		Wipe limit	10 µg/100 cm ²	Internal
Talc	14807-96-6	TWA OEL-RL (Respirable dust)	1 mg/m ³	ZA OEL
Further information: Recommended Limit				
		TWA OEL-RL (inhalable dust)	10 mg/m ³	ZA OEL
Further information: Recommended Limit				
Glycerine	56-81-5	TWA OEL-RL (Mist)	10 mg/m ³	ZA OEL
Further information: Recommended Limit				

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerine	Workers	Inhalation	Long-term local effects	56 mg/m ³
	Consumers	Ingestion	Long-term systemic effects	229 mg/kg bw/day
	Consumers	Inhalation	Long-term local effects	33 mg/m ³
Tocopherol	Workers	Inhalation		44 mg/m ³
	Workers	Skin contact		125 mg/kg bw/day
	Consumers	Inhalation		10,8 mg/m ³
	Consumers	Skin contact		62,5 mg/kg bw/day
	Consumers	Ingestion		6,25 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0,885 mg/l
	Marine water	0,0885 mg/l
	Intermittent use/release	8,85 mg/l

Lynestrenol Formulation

Version 3.4 Revision Date: 09.04.2021 SDS Number: 449559-00011 Date of last issue: 10.10.2020
Date of first issue: 15.01.2016

	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3,3 mg/kg dry weight (d.w.)
	Marine sediment	0,33 mg/kg dry weight (d.w.)
	Soil	0,141 mg/kg dry weight (d.w.)

8.2 Exposure controls**Engineering measures**

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

- Appearance : powder
- Colour : No data available
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available

SAFETY DATA SHEET



Lynestrenol Formulation



Version 3.4 Revision Date: 09.04.2021 SDS Number: 449559-00011 Date of last issue: 10.10.2020
Date of first issue: 15.01.2016

Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : Not applicable
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : Not applicable
Relative vapour density : Not applicable
Relative density : No data available
Density : No data available
Solubility(ies)
 Water solubility : No data available
 Partition coefficient: n-octanol/water : Not applicable
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
 Viscosity, kinematic : Not applicable
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available
Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

dling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:**Lynestrenol:**

Acute oral toxicity : LD50: > 1.000 - 8.000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Mouse): 110 mg/kg
Application Route: Intraperitoneal

Tocopherol:

Acute oral toxicity : LD50 (Rat): > 4.000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 3.000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Tocopherol:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Lynestrenol Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020
3.4 09.04.2021 449559-00011 Date of first issue: 15.01.2016

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Tocopherol:**

Species : Rabbit
Method : OECD Test Guideline 405
Result : No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Tocopherol:**

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : positive

Assessment : Probability or evidence of low to moderate skin sensitisation rate in humans

Germ cell mutagenicity

May cause genetic defects.

Components:**Lynestrenol:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Result: positive

Test Type: sister chromatid exchange assay
Result: positive

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: positive

Test Type: sister chromatid exchange assay
Species: Mouse
Application Route: Intraperitoneal injection
Result: positive

Test Type: dominant lethal test

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

Species: Mouse
 Application Route: Intraperitoneal
 Result: positive

Germ cell mutagenicity- Assessment : Positive result(s) from in vivo somatic cell mutagenicity tests in mammals. Evidence that the substance has potential to cause mutations to germ cells

Tocopherol:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative
 Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative
 Remarks: Based on data from similar materials

Carcinogenicity

Suspected of causing cancer.

Components:**Lynestrenol:**

Species : Mouse
 Application Route : Oral
 Exposure time : 80 weeks
 Result : positive
 Tumor Type : breast tumors, Liver
 Remarks : Benign and malignant tumor(s)

Species : Rat
 Application Route : Oral
 Exposure time : 80 weeks
 Result : positive
 Tumor Type : breast tumors

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in animal studies

Tocopherol:

Species : Rat
 Application Route : Ingestion
 Exposure time : 104 weeks
 Result : negative
 Remarks : Based on data from similar materials

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

Components:**Lynestrenol:**

- Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, males
Application Route: Oral
Fertility: LOAEL: 20 mg/kg body weight
Remarks: Impaired spermatogenesis
- Test Type: Fertility/early embryonic development
Species: Rat, females
Application Route: Oral
Fertility: LOAEL: 375 µg/kg
Result: Maternal toxicity observed., Effects on fertility
- Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Oral
Fertility: LOAEL: 1.300 µg/kg
Result: Effects on fertility, Postimplantation loss.
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0,1 mg/kg body weight
Result: Effects on foetal development
- Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 0,1 mg/kg body weight
Result: Effects on foetal development, Postimplantation loss.
- Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments., Positive evidence of adverse effects on sexual function and fertility from human epidemiological studies.

Tocopherol:

- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

Components:**Lynestrenol:**

Target Organs	:	Blood, Mammary gland, Uterus (including cervix), Ovary
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Tocopherol:**

Species	:	Rat
NOAEL	:	500 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Lynestrenol:**

Ingestion	:	Target Organs: Uterus (including cervix) Target Organs: breasts Target Organs: ovaries Target Organs: Blood Symptoms: Headache, Nausea, Abdominal pain, Rash, Dizziness, Tremors, Sweating, Vomiting, migraine, acne, breast tenderness, gynecomastia, menstrual irregularities, ovarian cysts Remarks: Used to prevent pregnancy
-----------	---	--

SECTION 12: Ecological information**12.1 Toxicity****Components:****Tocopherol:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
------------------	---	---

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 23,53 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
---	---	--

Toxicity to algae/aquatic	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 25,8
---------------------------	---	--

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

plants		mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		EC50 (Pseudokirchneriella subcapitata (green algae)): > 25,8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	:	EC50 : > 937 mg/l Exposure time: 30 min Method: ISO 8192 Remarks: Based on data from similar materials
Toxicity to fish (Chronic toxicity)	:	NOEC: > 100 mg/l Exposure time: 28 d Species: Oncorhynchus mykiss (rainbow trout) Remarks: Based on data from similar materials

12.2 Persistence and degradability**Components:****Tocopherol:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 20 % Exposure time: 28 d Method: OECD Test Guideline 301F
------------------	---	---

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
------------	---	--

12.6 Other adverse effects**Product:**

Endocrine disrupting potential	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
--------------------------------	---	---

SAFETY DATA SHEET



Lynestrenol Formulation



Version 3.4 Revision Date: 09.04.2021 SDS Number: 449559-00011 Date of last issue: 10.10.2020
Date of first issue: 15.01.2016

SECTION 13: Disposal considerations

13.1 Waste treatment methods

- Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
- Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
-

SECTION 14: Transport information

14.1 UN number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302	:	Harmful if swallowed.
H317	:	May cause an allergic skin reaction.
H340	:	May cause genetic defects.
H351	:	Suspected of causing cancer.
H360Fd	:	May damage fertility. Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure.

Full text of other abbreviations

Acute Tox.	:	Acute toxicity
Carc.	:	Carcinogenicity
Muta.	:	Germ cell mutagenicity
Repr.	:	Reproductive toxicity
Skin Sens.	:	Skin sensitisation
STOT RE	:	Specific target organ toxicity - repeated exposure
ZA OEL	:	South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits
ZA OEL / TWA OEL-RL	:	Long term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations

Lynestrenol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	449559-00011	Date of first issue: 15.01.2016

Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bio-accumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Muta. 1B	H340
Carc. 2	H351
Repr. 1A	H360Fd
STOT RE 2	H373

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN